Labetuzumab
Alternative Names: Anti-CEA monoclonal antibody MN 14; CEA-Cide; hCEA; hMN-14; IMMU-100; IMMU-14; Monoclonal antibody MN-14Latest Information Update: 24 Oct 2021
At a glance
- Originator Immunomedics
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Breast cancer; Colorectal cancer; Ovarian cancer
Most Recent Events
- 23 Oct 2020 Immunomedics has been acquired by Gilead Sciences
- 05 Jun 2003 Data presented at the 39th Annual Meeting of the American Society of Clinical Oncology (ASCO-2003) have been added to the Cancer pharmacodynamics section
- 04 Nov 2002 Preclinical data from a media release have been added to the Cancer pharmacodynamics section